Roche Entered into a Clinical Trial Supply Agreement with Galecto to Evaluate GB1211 + Tecentriq (atezolizumab) in P-IIa Trial for 1L Treatment of NSCLC
Shots:
- The companies collaborated to evaluate the safety, tumor shrinkage, clinical activity & immune biomarkers of Galectos GB1211 (galectin-3 inhibitor) + Roches Tecentriq (PD-L1 checkpoint inhibitor) in P-IIa trial in a ratio (1:1) in 70 patients with NSCLC. The P-IIa study is expected to start in 2022 & results are expected in mid-2023
- Galecto will be the sponsor of the study & retains all rights to GB1211 while Roche will provide clinical supply of Tecentriq
- In multiple preclinical models, GB1211 showed an anti-cancer effect & antifibrotic activity, was well-tolerated & had dose-dependent PK. Additionally, GB1211 is designed to treat multiple cancer and fibrotic diseases
Ref: PR Newswire | Image: Roche
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com